Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 680 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Antibiotic Therapy Clear all

Conditions: Mycobacterium Avium-Intracellulare Infection
Interventions: Interferon Gamma for Aerosol; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Appendicitis
Interventions: Non-operative treatment, Appendectomy; Other · Procedure
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 5 Years to 16 Years
Enrollment: 978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Antibiotic-associated Diarrhea, Clostridium Difficile
Interventions: Lactobacillus reuteri; Dietary Supplement
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bacterial Infections
Interventions: QPX7728, Placebo, QPX2014; Drug
Lead sponsor: Qpex Biopharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Serious Infections Due to Known or Suspected Gram-positive Pathogens
Interventions: TD-1607, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Infectious Diseases
Interventions: Ciprofloxacin, Non-quinolone antibiotic; Drug
Lead sponsor: Bayer; Industry
Eligibility: 2 Months to 16 Years
Enrollment: 1,029 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 66
States / cities: Mobile, Alabama • Fort Smith, Arkansas • Corona, California + 58 more

Conditions: Sinusitis, Bronchitis, Chronic, Pneumonia, Bacterial
Interventions: all macrolide antibiotics, all beta-lactam antibiotics; Drug
Lead sponsor: CPL Associates; Other
Eligibility: Up to 95 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Cystic Fibrosis
Interventions: Ethambutol, Rifampin, Azithromycin, Pancrelipase; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 16 Years to 45 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetic Foot Infections
Interventions: Surgical incision and drainage of diabetic foot infection, Short course antibiotics, Long course antibiotics; Procedure · Drug
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Obesity
Interventions: Standard Dose Group, Weight Based Group; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Community Acquired Pneumonia (CAP), Sinusitis, Strep Pharyngitis, Acute Otitis Media (AOM)
Interventions: Online Educational Modules, Prescribing Feedback Reports, Clinical Decision Support, Live, hybrid in-person and online educational sessions; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Months to 12 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
Interventions: Single-Dose Antibiotic, Multi-Dose Antibiotic; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Antibiotic Side Effect, Behavioral Changes
Interventions: CDC Core Elements of Outpatient Stewardship; Behavioral
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: Not listed
Enrollment: 700,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Vesicoureteral Reflux, Urinary Tract Infections
Interventions: Trimethoprim-Sulfamethoxazole, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Months to 71 Months
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 19
States / cities: Birmingham, Alabama • Wilmington, Delaware • Washington D.C., District of Columbia + 16 more

Conditions: Fractures, Open, Wounds and Injuries--Infections, Anti-Bacterial Agents, Fractures, Bone, Extremity Fracture Lower, Extremity Fractures Upper
Interventions: Vancomycin, Tobramycin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Skin and Subcutaneous Tissue Bacterial Infections
Interventions: Delafloxacin, Vancomycin, Aztreonam, Placebo; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 17
States / cities: Montgomery, Alabama • Anaheim, California • Chula Vista, California + 14 more

Conditions: Urinary Tract Infections
Interventions: Cystoscopic Fluid containing Neosporin G. U. Irrigant, Cystoscopy, Cystoscopic Fluid/Placebo; Drug · Procedure
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bacterial Infection, Anti-infective Agents, Breast Implantation
Interventions: Cefadroxil discontinued early, Cefadroxil until drain removal; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Pseudomonas Aeruginosa Pneumonia
Interventions: AR-105, Placebo; Drug
Lead sponsor: Aridis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 14
States / cities: Sacramento, California • San Diego, California • Jacksonville, Florida + 9 more

Conditions: Gram-negative Bacterial Infection
Interventions: Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4; Drug
Lead sponsor: Pfizer; Industry
Eligibility: Up to 39 Weeks
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • Indianapolis, Indiana + 4 more

Conditions: Alveolar Osteitis, Dry Socket, Infection
Interventions: IV Preoperative antibiotic or placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 13 Years and older
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: cefdinir (Omnicef), azithromycin; Drug
Lead sponsor: Abbott; Industry
Eligibility: 4 Years to 8 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2003
U.S. locations: 3
States / cities: Scottsdale, Arizona • St. Petersburg, Florida • Miamiville, Ohio

Conditions: Abscess
Interventions: Incision and drainage, Trimethoprim/Sulfamethoxazole (Bactrim), Placebo; Procedure · Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 6 Months to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy Volunteers
Interventions: Saccharomyces boulardii, Amoxicillin Clavulanate; Dietary Supplement · Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections

Appendectomy Versus Non-Operative Treatment For Acute Non-Perforated Appendicitis in Children

Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile

P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV

TD-1607 SAD Study in Healthy Subjects

BAY 0 9867 Cipro Pediatric Use Study (QUIP)

Outcomes of Patients Not Responding to Antibiotics in the Community

Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis

Diabetic Foot Infection Antibiotic Study

Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients

Reducing Antibiotic Use by Implementation of Stewardship in Primary and Urgent Care

Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

Improving Antibiotic Use in Urgent Care Facilities

Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)

Acute Application of Antibiotic Powder in Open Fracture Wounds

Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection

Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction

Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia

A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)

Antibiotic Efficacy in Third Molar Surgery

A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications

Antibiotic Therapy After Incision and Drainage for Abscess

Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota